Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
BörsenkürzelAMIX
Name des UnternehmensAutonomix Medical Inc
IPO-datumJan 29, 2024
CEOHauser (Bradley)
Anzahl der mitarbeiter8
WertpapierartOrdinary Share
GeschäftsjahresendeJan 29
Addresse21 Waterway Ave, Suite 300
StadtTHE WOODLANDS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl77380
Telefon18322777816
Websitehttps://autonomix.com/
BörsenkürzelAMIX
IPO-datumJan 29, 2024
CEOHauser (Bradley)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten